Advertisement


Nicholas C. Turner, MD, PhD, on Tackling Breast Cancer Diversity

2017 San Antonio Breast Cancer Symposium

Advertisement

Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Trust, discusses the challenges of treating metastatic breast cancer and how liquid biopsies can serve as a guide to genetic phenotypes.



Related Videos

Breast Cancer

Richard G. Gray, MSc, on Adjusting Adjuvant Chemotherapy Dosing: Results From an EBCTCG Analysis

Richard G. Gray, MSc, of the University of Oxford, discusses an Early Breast Cancer Trialists’ Collaborative Group meta-analysis of 21,000 women in 16 randomized trials, which showed that increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or sequentially administering treatment significantly reduces disease recurrence and breast cancer mortality (Abstract GS1-01).

Breast Cancer

Lynn J. Howie, MD, on ER+ Metastatic Breast Cancer: An FDA Treatment Analysis

Lynn J. Howie, MD, of the U. S. Food & Drug Administration, discusses a pooled analysis of outcomes of older women with hormone receptor–positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine-based therapy (Abstract GS5-06).

Breast Cancer

Joseph A. Sparano, MD, on Stage II–III Breast Cancer and CTCs

Joseph A. Sparano, MD, of Montefiore Medical Center/Albert Einstein College of Medicine, discusses findings that suggest circulating tumor cells 5 years after diagnosis are prognostic for late recurrence in operable stage II–III breast cancer (Abstract GS6-03).

Breast Cancer

Matteo Lambertini, MD, on Preserving Fertility in Patients With Early Breast Cancer: Pooled Analysis

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses the results of five clinical trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients (Abstract GS4-01).

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: the PADMA Trial

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses a study evaluating palbociclib plus endocrine treatment vs a chemotherapy-based treatment strategy in patients with hormone receptor–positive, HER2-negative metastatic breast cancer (Abstract OT3-05-04).

Advertisement

Advertisement




Advertisement